Baxter International Inc.

Baxter International Inc.(BAX)股票分析

$25.280

-0.470 (-1.86%)收盘时

Loading chart…
最高
25.985
开盘
25.950
成交量加权均价
25.47
成交量
4.41M
市值
17.08B
最低
25.133
成交额
112.23M
企业价值/息税折旧摊销前利润(TTM)
7.82

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

AI 分析 of Baxter International Inc. (BAX)

买入

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.

估值指标

Baxter International Inc.(BAX)当前预期市盈率为 11.57,5 年平均预期市盈率为 13.85。

预期市盈率

合理
5 年均值 P/E
13.85
当前P/E
11.57
高估
17.41
低估
10.28

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
11.75
当前EV/EBITDA
7.82
高估
14.90
低估
8.60

预期市销率

合理
5 年均值 P/S
1.48
当前P/S
1.12
高估
2.03
低估
0.94

Alphio AI 对 BAX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BAX

$28.00

情景价格

基

基准

基准 · 50%BAX

$25.49

情景价格

悲

悲观

悲观 · 25%BAX

$18.18

情景价格

持有 BAX 的大户

R

RWC Partners Limited

+ 持有BAX

+8.80%

3个月收益率

E

Edmond de Rothschild Asset Management (France)

+ 持有BAX

+7.54%

3个月收益率

P

Pzena Investment Management, Inc.

+ 持有BAX

+6.58%

3个月收益率

G

Greenhaven Associates Inc

+ 持有BAX

+3.20%

3个月收益率

F

First Pacific Advisors, LP

+ 持有BAX

+0.94%

3个月收益率

T

Tontine Management, LLC

+ 持有BAX

-15.67%

3个月收益率

事件时间线

2026-08-19 (ET)

08:30:00

Baxter International Appoints John Rogers as CFO

2026-08-04 (ET)

09:00:00

Baxter International Launches Cash Tender Offers Up to $500M

2026-07-30 (ET)

09:00:00

Microsoft's Strong Earnings Boosts Stock Futures Rebound

07:30:00

Baxter Reports Q2 Revenue of $2.96B, Exceeding Expectations

07:30:00

Company Raises Full-Year Financial Outlook to $1.91

资讯

BAX 常见问题 —— 由 Alphio AI 解答

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易